The economic impact of esophageal variceal hemorrhage: Cost‐effectiveness implications of endoscopic therapy
Ian M. Gralnek, Dennis M. Jensen, Thomas O. Kovacs, Rome Jutabha, Gustavo A. Machicado, Jeffrey Gornbein, Joy King, Susie Cheng, Mary Ellen Jensen – 30 December 2003 – Esophageal variceal hemorrhage (EVH) is a serious and expensive sequela of chronic liver disease, leading to increased utilization of resources. Today, endoscopic sclerotherapy (ES) and endoscopic ligation (EL) are the accepted, community standards of endoscopic treatment of patients with EVH. However, there are no published studies comparing the economic costs of treating EVH using these interventions.